Medical Developments International (ASX:MVP) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:MVP Medical Developments International Ltd ASX:MVP
54 GF Score
Price A$0.41
GF Value A$0.65
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medical Developments International Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Medical Developments International Quality Rank Related Terms

ASX:MVP
54GF Score
Medical Developments International Ltd ASX:MVP
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medical Developments International (ASX:MVP) Overvalued in 2026?

Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued. The current stock price of A$0.41 is trading 37.7% below its estimated GF Value™ of A$0.65. GuruFocus considers Medical Developments International to be Significantly Undervalued.

Key valuation signals for ASX:MVP:

  • Quality Rank:
  • GF Value™: A$0.65 vs. price of A$0.41 (37.7% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medical Developments International Business Description

Other Exchanges MDDVF:USAM5D:Germany
Address 4 Caribbean Drive, Scoresby, VIC, AUS, 3179
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
54GF Score

Get the complete analysis for ASX:MVP

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.41
Price
A$0.65
GF Value